Drug
Uproleselan clinical trials
Also written GMI-1271.
- studies test it
- 16
- open now
- 0
- in phase 3
- 3
- first study started
- 2014
How studies write it
Studies that test it under each name
Name
Studies by the year they started
16 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 5
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 7
GlycoMimetics Incorporated (7) · National Cancer Institute (NCI) (2) · Apollomics Inc. (2) · M.D. Anderson Cancer Center (1) · Washington University School of Medicine (1) · Brian Jonas (1) · Malika Kapadia (1) · Lena Napolitano, MD (1)
Often tested with
Tested in the same studies.
Cytarabine (2) · Fludarabine (1) · Cladribine (1) · Filgrastim (1) · Azacitidine (1) · Venetoclax (1) · Busulfan (1)
Studies
Open first, then newest update. How each study uses uproleselan is read from its arms, and is right about nine times in ten.
Testing it · 16
- Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid LeukemiaCompletedPhase 1/2M.D. Anderson Cancer CenterNCT04848974Written as Uproleselan
- Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell MembraneActive, not recruitingPhase 1National Cancer Institute (NCI)NCT05146739Written as Uproleselan
- Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid LeukemiaTerminatedPhase 1Brian JonasNCT04964505Written as Uproleselan
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction ChemotherapyActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT03701308Written as Uproleselan
- Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML PatientsCompletedPhase 1Apollomics Inc.NCT04839341Written as Uproleselan
- Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLTerminatedPhase 3Apollomics Inc.NCT05054543Written as Uproleselan
- Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AMLTerminatedPhase 1Malika KapadiaNCT05569512Written as Uproleselan
- Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid LeukemiaTerminatedPhase 3GlycoMimetics IncorporatedNCT03616470Written as Uproleselan
- Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)CompletedPhase 2Washington University School of MedicineNCT04682405Written as Uproleselan
- Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 PneumoniaTerminatedPhase 1/2Lena Napolitano, MDNCT05057221Written as Uproleselan
- A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple MyelomaCompletedPhase 1GlycoMimetics IncorporatedNCT02811822Written as GMI-1271
- Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)TerminatedPhase 1/2GlycoMimetics IncorporatedNCT02744833Written as GMI-1271
- A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)CompletedPhase 1GlycoMimetics IncorporatedNCT03606447Written as Uproleselan
- Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult SubjectsCompletedPhase 1GlycoMimetics IncorporatedNCT02271113Written as GMI-1271
- Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy VolunteersCompletedPhase 1GlycoMimetics IncorporatedNCT02168595Written as GMI-1271
- A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult SubjectsCompletedPhase 1GlycoMimetics IncorporatedNCT02703051Written as GMI-1271
Given in every arm · 1 — uproleselan is usual care beside what is tested
Codes
What other systems call uproleselan · ClinicalTrials.gg INT001195
- MeSH (NLM) C000654285uproleselanConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) PE952ANF83UPROLESELANConfirmed FDA, NLM
- NCI Thesaurus C119743UproleselanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654285 | uproleselan | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | PE952ANF83 | UPROLESELAN | Confirmed FDA, NLM |
| NCI Thesaurus | C119743 | Uproleselan | One source FDA |
Also registered as uproleselan sodium (UNII 17ZJN0Q4CJ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.